An analysis of the stock market impact of material weakness disclosures, provided by Compliance Week subscriber Dan Spiegelman, SVP and CFO of Palo Alto based CV Therapeutics.

Intelligence, benchmarking, and certification for risk and compliance leaders, from the institution setting the standard since 1922.
An analysis of the stock market impact of material weakness disclosures, provided by Compliance Week subscriber Dan Spiegelman, SVP and CFO of Palo Alto based CV Therapeutics.
We'll send a verification code to %EMAIL%.